Roxi-AI surfaces outcome-linked risks across programs and peers, highlights what’s fixable, and shows where to focus capital – so portfolio reviews and CI updates drive faster, defendable decisions avoiding expensive mistakes.
Outcome-linked scientific, clinical and regulatory signals flag fragile designs, endpoints, and comparators before they become expensive.
Prioritized, evidence-backed moves with expected impact – so teams know what to fix first.
Like-for-like risk profiling across peers and competitors, updating in real time, enables a smart competitive response strategy across all teams.
An AI research agent for pharma: tuned to life-sciences data and Roxi-AI risk signals, it helps R&D, medical, and commercial teams run deep searches and get cited, explainable answers with governance controls.
BD with confidence: Evaluate candidates with confidence using Roxi-Ai’s proprietary risk benchmarking and predictive models
Capital allocation: Surface capital sinks and advance programs with a greater likelihood of success.
Clear trade-offs: Rehearse scenarios across cost, time, and likelihood of success- decide with confidence.
Portfolio diagnostic: Evaluate your pipeline, flag and benchmark risks, and derisk the pipeline.
Design with foresight: detect protocol and comparator risks early; prepare for regulatory interactions.
Prioritize derisking moves: Model the impact of strategic alternatives on program-wide outcomes – derisk with confidence.
